Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harmin Chima

Optometrist Dublin, OH Doctor of Optometry

NPI 1538542444 CMS profile 1349277

5043 Tuttle Crossing Blvd Ste 238, Dublin, OH 43016

Open in the dashboard

General payments

$91,228

329 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harmin Chima of Dublin, OH is reported in the CMS Open Payments database as having received $91,228 across 329 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,704 40
2024 General $9,828 38
2023 General $14,928 58
2022 General $22,004 69
2021 General $11,393 45
2020 General $10,175 29
2019 General $10,196 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harmin Chima
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Harmin Chima were reported at $12,704. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Harmin Chima Optometrist median Middle half National median
2019 $10,196 $159 $67–$371 $163
2020 $10,175 $72 $29–$165 $114
2021 $11,393 $125 $46–$292 $132
2022 $22,004 $162 $66–$374 $149
2023 $14,928 $177 $72–$406 $160
2024 $9,828 $188 $77–$427 $164
2025 $12,704 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $85,021 229 payments
  2. Alcon Vision LLC $3,046 35 payments
  3. Johnson & Johnson Vision Care, Inc. $1,274 31 payments
  4. Bausch & Lomb, a division of Bausch Health US, LLC $414 7 payments
  5. Sight Sciences, Inc. $316 8 payments
  6. Visioneering Technologies, Inc. $200 1 payment
  7. Tarsus Pharmaceuticals, Inc. $172 2 payments
  8. Thea Pharma Inc. $160 2 payments
  9. Kala Pharmaceuticals, Inc. $146 2 payments
  10. AbbVie, Inc. $135 4 payments
  11. Other $345 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $39,119 32 payments
  2. Travel and Lodging $31,196 48 payments
  3. Food and Beverage $12,514 231 payments
  4. Consulting Fee $7,390 13 payments
  5. Education $779 3 payments
  6. Honoraria $200 1 payment
  7. Entertainment $30 1 payment
Products named General payments · program years 2019–2025
  1. MyDay Contact Lens $30,781 86 payments
  2. Clariti Contact Lens $15,140 36 payments
  3. Multiple Brands Contact Lens $11,513 24 payments
  4. CVI Contact Lens $8,044 35 payments
  5. Biofinity Contact Lens $5,795 10 payments
  6. Non-Product Brand Specific $4,472 16 payments
  7. DAILIES $1,818 17 payments
  8. MiSight Contact Lens $1,448 12 payments
  9. Acuvue $1,174 25 payments
  10. AIR OPTIX $727 5 payments
  11. Other $2,736 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

48

Median for Optometry: 120

Drug cost

$3,169

Median for Optometry: $8,864

Branded share of claims

0%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cyclosporine Generic 13 $2,944
Latanoprost Generic 35 $225

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$5,953

Medicare's payments for the services billed

Medicare patients

69

Average age 72

Services billed

154

36 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 39%
Diabetes 30%
Chronic kidney disease 25%
Ischemic heart disease 19%
Depression 19%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

329 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record